1Jamali F.Stereochemistry and bioequivalence[J].Clin Phar- macol, 1992,32 (10) :930.
2Brocks DR.Drug disposition in three dimensions: an up- date on stereoselectivity in pharmacokinetics[J]. Bio- pharm Drug Dispos, 2006,27(8) : 387.
3Midha KK, Mckay G, Rawson M J, et al.The impact of ste- reoisomerism in bioequivalence studies[J]. J Pharm Sci, 1998,87(7) :797.
4European Agency for the evaluation of medicinal products (EMEA), committee for Proprietary Medicinal Product ( CPMP ).Note for guidance on the investigetion of bio- availability and bieoequivalence[EB/OL ].http : //www.ega- generics.com/doc/emea_bioquiv-1401-98.pdf.2001-07- 26.2010-07-15.
5Health Canada.Guidance for industry stereochemical is- sues in chiral drug development[EB/OL].http : //www.hc-sc. gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/chem/ stereo-eng.php.2000-02-14.2010-07-15.
6Food and Drug Administration. Guidance for industry on bioavailability and bioequivalence studies for orally ad- ministered drug products-general considerations[EB/OL ]. http://google2.fda.gov/search?q=guidance + for+industry+ bioavailability+ and+bioequivalence+ studies&client=-FDA gov&site=FDAgov&lr=&proxystylesheet=FDAgov&out- put=xml_no_dtd&getfields=*&x=10&y=6.2003-10-01. 2010-07-15.
7Srinivas NR. Role of stereoselective assays in bioequiv- alence studies of racemic drugs: have we reached a con- sensus? [J]. J Clin Pharmacol, 2004,44 (2) : 115.
8Mehvar R, Jamali F.Bioequivalence of chiral drugs. Stereo- specific versus non-stereospecific methods[J].Clin Phar- macokinet, 1997,33 (2) : 122.
10Karim A. Enantioselective assays in comparative bioavail- ability studies of racemic drug formulations: nice to know or need to know? [J]. J Clin Pharmacol, 1996, 36 (6) :490.
4[1]Aarons L, Hopkins K, Rowland M, et al. Route of administration and sex differences in the pharmacokinetics of asprin, administered as its lysine salt[J]. Pharm Res, 1989;6:660-666.
5[2]Ho PC, Triggs EJ, Bourn DWA, et al. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites[J]. Br J Clin Pharmacol, 1985;19:675-684.
6[3]Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms[J]. J Pharmacol Exp Ther, 1995;275:1011-1018.
7[4]Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics[J]. Clin Pharmacokinet, 2002;41:329-342.
8[5]Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450 Ⅲ A(CYP3A) activity[J]. Clin Pharmacol Ther,1992; 52:265-273.
9[6]Rugstad HE, Hundal O, Holme I, et al. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events[J]. Clin Rheumatol, 1986;5:389-398.
10[7]Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers[J]. Br J Clin Pharmacol, 2001 ;51:169-173.
